A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease

Steroid-refractory (SR) acute graft-versus-host disease (aGvHD) remains a significant complication after allogeneic hematopoietic cell transplantation. Systemic corticosteroids are first-line therapy for aGvHD, but apart from ruxolitinib, there are no approved treatments for SR aGvHD. Vedolizumab is...

Descripción completa

Detalles Bibliográficos
Autores principales: Fløisand, Yngvar, Schroeder, Mark A., Chevallier, Patrice, Selleslag, Dominik, Devine, Steven, Renteria, Anne S., Mohty, Mohamad, Yakoub-Agha, Ibrahim, Chen, Chunlin, Parfionovas, Andrejus, Quadri, Syed, Jansson, Johan, Akbari, Mona, Chen, Yi-Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486663/
https://www.ncbi.nlm.nih.gov/pubmed/34108672
http://dx.doi.org/10.1038/s41409-021-01356-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486663/
https://www.ncbi.nlm.nih.gov/pubmed/34108672
http://dx.doi.org/10.1038/s41409-021-01356-0

Ejemplares similares